Loading company
Eton Pharmaceuticals, Inc.
ETON · Nasdaq · ·
Next earnings: November 5, 2026
$59.25+0.1%Sep 29 close
- 1M
- -0.9%
- 6M
- +162.4%
- 1Y
- +172.7%
- 5Y
- +1,080.3%
ETON · Nasdaq · ·
Next earnings: November 5, 2026
$59.25+0.1%Sep 29 close
Eton Pharmaceuticals, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $37.6M | $18.9M | +98.59% |
| Profit | $11.6M | -$2.6M | +547.89% |
| Profit per share | $0.35 | -$0.06 | +683.33% |
| Free Cash Flow | $7.3M | $8M | -8.78% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eleven commercial rare disease products: KHINDIVI ®, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, IMPAVIDO® (September 2026 launch), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ASN-001, AMGLIDIA®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Eton Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Eton Pharmaceuticals, Inc. has no earnings call transcript available.